Formycon AG (WBO:FYB) Cyclically Adjusted PB Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:FYB Formycon AG WBO:FYB
43 GF Score
Price €19.86
GF Value €32.04
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Formycon AG  (WBO:FYB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Formycon AG Cyclically Adjusted PB Ratio Related Terms


Formycon AG Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Formycon AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Cyclically Adjusted PB Ratio Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.30 14.47 6.27 4.56 1.86

Formycon AG Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.56 0.00 1.86 0.00

WBO:FYB vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Formycon AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Formycon AG's Cyclically Adjusted PB Ratio falls into.


WBO:FYB
43GF Score
Formycon AG WBO:FYB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Formycon AG's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Formycon AG's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=22.585/129.3606*129.3606
=22.585

Current CPI (Dec25) = 129.3606.

Formycon AG Annual Data

Book Value per Share CPI Adj_Book
201612 2.296 101.217 2.934
201712 2.807 102.617 3.539
201812 3.528 104.217 4.379
201912 4.821 105.818 5.894
202012 6.185 105.518 7.583
202112 5.051 110.384 5.919
202212 23.569 119.345 25.547
202312 31.318 123.773 32.732
202412 26.146 127.041 26.623
202512 22.585 129.361 22.585

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Formycon AG (WBO:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €19.86 is trading 38% below its estimated GF Value™ of €32.04. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for WBO:FYB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €32.04 vs. price of €19.86 (38% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Formycon AG Business Description

Other Exchanges 0W4N:UKFYB:Germany
Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
43GF Score

Get the complete analysis for WBO:FYB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.86
Price
€32.04
GF Value